MedTrace Logo

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

NCT00168896 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2006-02-14

No results posted yet for this study

Summary

Comparison of two combination chemotherapies in the treatment of patients with SLCL

Conditions

Interventions

DRUG

Carboplatin plus Irinotecan vs Carboplatin plus Etoposide

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Ulrich Keilholz, MD · Charité Campus Benjamin Franklin University Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2006-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168896 on ClinicalTrials.gov